John Flanagan
26Patents
9h-index
43Co-inventors
75Inventor score
Filing activity: Dec 14, 1993 → Mar 21, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8592362B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 53 | Active |
| US9095584B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 50 | Active |
| US9545397B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 48 | Active |
| US10813921B2 | Method to predict response to pharmacological chaperone treatment of diseases | Physics | 37 | Active |
| USRE48608E1 | Method to predict response to pharmacological chaperone treatment of diseases | General | 35 | Active |
| US5795734A | EPH receptor ligands, and uses related thereto | Chemistry; Metallurgy | 23 | Expired |
| US5789182A | System for assaying binding to a heparin-binding growth factor receptor | Physics | 21 | Expired |
| US9404100B2 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease | Chemistry; Metallurgy | 16 | Active |
| US9303249B2 | High concentration α-glucosidase compositions for the treatment of Pompe disease | Chemistry; Metallurgy | 14 | Active |
| US6399326B1 | Nucleic acids encoding neural/pancreatic receptor tyrosine phosphatase | Chemistry; Metallurgy | 9 | Expired |
| US9744188B2 | Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigma | Human Necessities | 5 | Active |
| US10046033B2 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease | Chemistry; Metallurgy | 4 | Active |
| US10512677B2 | High concentration alpha-glucosidase compositions for the treatment of pompe disease | Chemistry; Metallurgy | 4 | Active |
| US7381708B2 | Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eye | Chemistry; Metallurgy | 2 | Expired |
| US11808772B2 | Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status | Physics | 1 | Active |
| US6268476A | EPH receptor ligands, and uses related thereto | Chemistry; Metallurgy | 1 | Expired |
| US12208095B2 | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders | Human Necessities | 0 | Active |
| US7662796B2 | Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1 | Chemistry; Metallurgy | 0 | Active |
| US6919313B2 | Protein waving a PDZ and a RGS domain | Physics | 0 | Expired |
| US6777536B1 | EPH receptor ligands, and uses related thereto | Chemistry; Metallurgy | 0 | Expired |
| US11439615B2 | Lipoxin and lipoxin analogue mediated neuroprotection and treatments | Human Necessities | 0 | Active |
| US5801000A | Detection and isolation of receptors | Emerging Cross-Sectional Technologies | 0 | Expired |
| US8242256B2 | siRNA useful to supress expression of EIF-5A1 | Chemistry; Metallurgy | 0 | Active |
| US5554499A | Detection and isolation of ligands | Emerging Cross-Sectional Technologies | 0 | Expired |
| US11278599B2 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.